2021Äê4ÔÂ12ÈÕ £¬£¬£¬£¬£¬£¬¸´ºêººÁØ£¨Ïã¸ÛÁª½»Ëù´úÂ룺2696£©Ðû²¼¹«Ë¾×ÔÖ÷¿ª·¢µÄºº´ïÔ¶?£¨HLX03 £¬£¬£¬£¬£¬£¬°¢´ïľµ¥¿¹×¢ÉäÒº£©ÓÃÓÚÖÎÁƳÉÈË·ÇѬȾÐÔÖÐÐÄ¡¢ºóºÍÈ«ÆÏÌÑĤÑ×µÄÔö²¹ÉêÇ루sNDA£©ÓÚ¿ËÈÕÕýʽ»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨NMPA£©Åú×¼¡£¡£¡£¡£¡£¡£¡£¡£ÕâÊǼÌÀà·çʪÊàŦÑס¢Ç¿Ö±ÐÔ¼¹ÖùÑס¢Òøм²¡Ö®ºó £¬£¬£¬£¬£¬£¬ºº´ïÔ¶?ÔÚº£ÄÚ»ñÅúµÄµÚËĸö˳Ӧ֢¡£¡£¡£¡£¡£¡£¡£¡£
ºº´ïÔ¶?ÊǸ´ºêººÁØƾ֤ÖйúÉúÎïÀàËÆÒ©Ö¸µ¼ÔÔò×ÔÖ÷¿ª·¢µÄµ¥¿¹ÉúÎïÀàËÆÒ© £¬£¬£¬£¬£¬£¬Ò²Êǹ«Ë¾Ê׿îÖÎÁÆ×ÔÉíÃâÒß¼²²¡µÄ²úÆ·¡£¡£¡£¡£¡£¡£¡£¡£2020Äê12Ô £¬£¬£¬£¬£¬£¬ºº´ïÔ¶»ñ¹ú¼ÒÒ©¼à¾ÖÅú×¼ÉÏÊÐ £¬£¬£¬£¬£¬£¬ÓÃÓÚÀà·çʪÊàŦÑס¢Ç¿Ö±ÐÔ¼¹ÖùÑ׺ÍÒøм²¡µÄÖÎÁÆ¡£¡£¡£¡£¡£¡£¡£¡£Í¬Ê± £¬£¬£¬£¬£¬£¬¸´ºêººÁØÏò¹ú¼ÒÒ©¼à¾ÖÉêÇ뽫ºº´ïÔ¶?˳Ӧ֢ÍâÍÆÔöÌí·ÇѬȾÐÔÆÏÌÑĤÑ× £¬£¬£¬£¬£¬£¬½øÒ»²½À©Õ¹ºº´ïÔ¶?ÔÚÑÛ¿ÆÖÎÁÆÁìÓòµÄÓ¦Óà £¬£¬£¬£¬£¬£¬²¢ÓÚ2021Äê1Ô»ñµÃsNDAÊÜÀí¡£¡£¡£¡£¡£¡£¡£¡£ÉÏÊк󺺴ïÔ¶?ÔÚº£ÄÚµÄÉÌÒµÏúÊÛÓɽËÕÍò°îÈÏÕæ £¬£¬£¬£¬£¬£¬½ËÕÍò°î½¨ÓÐÏ൱¹æÄ£µÄ·çʪÃâÒßÊÂÒµ²¿ºÍÃæÏòÁÉÀ«Êг¡µÄ»ìÏßÏúÊÛÍÅ¶Ó £¬£¬£¬£¬£¬£¬ÓªÏú²½¶Ó¾ß±¸½Ï¸ßµÄרҵÏàͬÄÜÁ¦ºÍҽѧ֪ʶˮƽ £¬£¬£¬£¬£¬£¬ÇÒ¾ßÓзçʪÖÎÁÆÁìÓò²úÆ·µÄÀÖ³ÉÉÌÒµ»¯ÂÄÀú¡£¡£¡£¡£¡£¡£¡£¡£×èÖ¹ÏÖÔÚ £¬£¬£¬£¬£¬£¬ºº´ïÔ¶?ÒÑÕýʽÄÉÈë¹ú¼ÒÒ½±£Ä¿Â¼ £¬£¬£¬£¬£¬£¬²¢ÀÖ³ÉÁËÍê³ÉÁËÔÚÌìϹæÄ£ÄÚ22¸öÊ¡ÊеĹÒÍøÊÂÇé¡£¡£¡£¡£¡£¡£¡£¡£ºóÐø¹«Ë¾Ò²½«¼ÌÐøÓë½ËÕÍò°îÅäºÏ¿ªÕ¹ºº´ïÔ¶?µÄÏúÊÛ×¼±¸ÊÂÇé £¬£¬£¬£¬£¬£¬ÔÚ·çʪÁìÓò£¨Ç¿Ö±ÐÔ¼¹ÖùÑס¢Àà·çʪÊàŦÑ×(RA)˳Ӧ֢£©ÓëƤ·ôÁìÓò£¨Òøм²¡Ë³Ó¦Ö¢£©Ë«¹ì²¢½ø £¬£¬£¬£¬£¬£¬ÓÚ2021ÄêÄÚʵÏÖ¸ü¶àר¿ÆÒ½ÉúºÍDTPÒ©·¿/Ò½ÔºµÄÁýÕÖ £¬£¬£¬£¬£¬£¬Ê¹µÃºº´ïÔ¶?ÔÚ¡°¾¼Ã¿É¼°¡±µÄ»ù´¡ÉÏʵÏÖ¡°ÇþµÀ¿É¼°¡± £¬£¬£¬£¬£¬£¬Á¦ÕùʵÏÖ»¼Õß¡°ÂòÒ©²»³öÏØ¡±µÄÄ¿µÄ¡£¡£¡£¡£¡£¡£¡£¡£
»ùÓÚºº´ïÔ¶?ÓëÔÑа¢´ïľµ¥¿¹¼äÒÑÓеÄÏàËÆÐÔÑо¿ £¬£¬£¬£¬£¬£¬·ÇѬȾÐÔÆÏÌÑĤÑ×Óë´ËÇ°ÒÑ»ñÅú˳Ӧ֢×÷ÓûúÖÆÏàͬ £¬£¬£¬£¬£¬£¬ÇÒÒªº¦ÁÙ´²ÊÔÑéÑ¡ÔñÁËÃô¸ÐÈËȺ¼°ºÏÊʵÄ˳Ӧ֢ £¬£¬£¬£¬£¬£¬Óгä·ÖµÄÇå¾²ÐÔºÍÃâÒßÔÐÔÊý¾Ý £¬£¬£¬£¬£¬£¬Çкϡ¶ÉúÎïÀàËÆÒ©Ñз¢ÓëÆÀ¼ÛÊÖÒÕÖ¸µ¼ÔÔò£¨ÊÔÐУ©¡·¡¢¡¶°¢´ïľµ¥¿¹×¢ÉäÒºÉúÎïÀàËÆÒ©ÁÙ´²ÊÔÑéÖ¸µ¼ÔÔò¡·µÈº£ÄÚ¹æÔòÕþ²ß¶Ô˳Ӧ֢ÍâÍƵÄÒªÇ󡣡£¡£¡£¡£¡£¡£¡£´Ë´Î £¬£¬£¬£¬£¬£¬ºº´ïÔ¶?ÍâÍÆÐÂÔö·ÇѬȾÐÔÆÏÌÑĤÑ×˳Ӧ֢ £¬£¬£¬£¬£¬£¬½«½øÒ»²½À©Õ¹¸Ã²úÆ·ÔÚÑÛ¿ÆÖÎÁÆÁìÓòµÄÓ¦Óà £¬£¬£¬£¬£¬£¬Îªº£ÄÚ×ÔÉíÃâÒß¼²²¡»¼Õß´øÀ´¸ü¶à¿É¼ç¸ºµÄ¡¢ÓÅÖʵÄÓÃÒ©Ñ¡Ôñ¡£¡£¡£¡£¡£¡£¡£¡£
ÏÖÔÚ £¬£¬£¬£¬£¬£¬¹«Ë¾Ò²ÕýÆð¾¢ÍýÏ뺺´ïÔ¶?ÆäËûÐÂÔö˳Ӧ֢µÄÔö²¹ÉêÇëÊÂÇé £¬£¬£¬£¬£¬£¬Ò»Ö±ÍØ¿íºº´ïÔ¶?ÔÚ¸ü¶à¼²²¡ÁìÓòÖеÄÖÎÁÆ £¬£¬£¬£¬£¬£¬Ò»Á¬Îª¸ü¶à»¼Õß´øÀ´ÐµÄÖÎÁÆÑ¡Ôñ¡£¡£¡£¡£¡£¡£¡£¡£Ëæןº´ïÔ¶?µÄÀÖ³ÉÉÏÊкÍÖð²½ÐÂÔö¸ü¶à˳Ӧ֢ £¬£¬£¬£¬£¬£¬¸´ºêººÁؽ«Ð¯ÊÖ½ËÕÍò°îÅäºÏÍƽøºº´ïÔ¶?µÄÉÌÒµ»¯ £¬£¬£¬£¬£¬£¬³ä·ÖÑéÕ¹¸÷×ÔÓÅÊÆ £¬£¬£¬£¬£¬£¬ÇÐʵ×ÊÖúÿһ¸öÐèÒªÉúÎïÖƼÁÖÎÁƵÄ×ÔÉíÃâÒß»¼Õß¡°Ó¦Öξ¡ÖΡ±¡£¡£¡£¡£¡£¡£¡£¡£
¹ØÓÚ·ÇѬȾÐÔÆÏÌÑĤÑ×
·ÇѬȾÐÔÆÏÌÑĤÑ×ÊÇÒ»×éÃâÒ߽鵼µÄÑÛÄÚÑ×Ö¢ÐÔ¼²²¡ £¬£¬£¬£¬£¬£¬¿ÉÄÜÒýÆð»¼ÕߺçĤճÁ¬¡¢Çà¹âÑÛ¡¢°×ÄÚÕÏ¡¢»Æ°ßË®Öס¢ÊÓÍøĤ²¡±äµÈ²¢·¢Ö¢ £¬£¬£¬£¬£¬£¬µ¼ÖÂÊÓÁ¦ÊÜËðÉõÖÁʧÃ÷ £¬£¬£¬£¬£¬£¬Í¨³£ÓëÃâÒß½é·öÒý·¢µÄϵͳÐÔ¼²²¡ÈçÒøм²¡¡¢Ç¿Ö±ÐÔ¼¹ÖùÑ×µÈÅäºÏ±¬·¢¡£¡£¡£¡£¡£¡£¡£¡£ÊÓ²ìÏÔʾ £¬£¬£¬£¬£¬£¬ÆÏÌÑĤÑ×»¼²¡ÂÊΪ152/ 100000[1] £¬£¬£¬£¬£¬£¬ÆäÖзÇѬȾÐÔÆÏÌÑĤÑ×»¼ÕßÕ¼±È´ï41%-55%-2 £¬£¬£¬£¬£¬£¬Òò´ËÆ仼²¡ÂÊÔ¤¼ÆΪ62.3-83.6/ 100000¡£¡£¡£¡£¡£¡£¡£¡£ÏÖÔÚ £¬£¬£¬£¬£¬£¬ÌÇƤÖʼ¤ËØÈÔΪÖÎÁÆ·ÇѬȾÐÔÆÏÌÑĤÑ×µÄÖ÷ÒªÖÎÁÆÒ©Îï £¬£¬£¬£¬£¬£¬È»¶øÕâÒ»¼Æ»®²¢·ÇÊÊÓÃÓÚËùÓеĻ¼Õß £¬£¬£¬£¬£¬£¬²¢ÇÒ¿ÉÄÜÅãͬÑÏÖصĸ±×÷Óᣡ£¡£¡£¡£¡£¡£¡£½üÄêÀ´ £¬£¬£¬£¬£¬£¬TNF-¦ÁÒÖÖƼÁÈç°¢´ïľµ¥¿¹ÔÚÐí¶à¹ú¼Ò±»Åú×¼ÓÃÓÚÖÎÁÆ·ÇѬȾÐÔÆÏÌÑĤÑס£¡£¡£¡£¡£¡£¡£¡£Ñо¿Åú×¢ £¬£¬£¬£¬£¬£¬°¢´ïľµ¥¿¹ÔÚ·ÇѬȾÐÔÆÏÌÑĤÑ×µÄÖÎÁÆÖÐÕ¹ÏÖ³ö½ÏºÃµÄÁÆЧ £¬£¬£¬£¬£¬£¬ÇÒ¾ßÓÐÇå¾²³¤ÆÚ £¬£¬£¬£¬£¬£¬²»Á¼·´Ó¦Ð¡µÈÌص㠣¬£¬£¬£¬£¬£¬Îª·ÇѬȾÐÔÆÏÌÑĤÑ×»¼Õß´øÀ´Á˸ü¶àµÄÓÃÒ©Ñ¡Ôñ-1¡£¡£¡£¡£¡£¡£¡£¡£
¹ØÓÚ¸´ºêººÁØ
¸´ºêººÁØ£¨2696.HK£©ÊÇÒ»¼Ò¹ú¼Ê»¯µÄÁ¢ÒìÉúÎïÖÆÒ©¹«Ë¾ £¬£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚΪȫÇò»¼ÕßÌṩ¿É¼ç¸ºµÄ¸ßÆ·ÖÊÉúÎïÒ© £¬£¬£¬£¬£¬£¬²úÆ·ÁýÕÖÖ×Áö¡¢×ÔÉíÃâÒß¼²²¡¡¢ÑۿƼ²²¡µÈÁìÓò £¬£¬£¬£¬£¬£¬ÒÑÔÚÖйúÉÏÊÐ3¿î²úÆ· £¬£¬£¬£¬£¬£¬ÔÚÅ·ÃËÉÏÊÐ1¿î²úÆ· £¬£¬£¬£¬£¬£¬2¿î²úÆ·»ñµÃÖйúÉÏÊÐ×¢²áÉêÇëÊÜÀí¡£¡£¡£¡£¡£¡£¡£¡£×Ô2010Ä꽨ÉèÒÔÀ´ £¬£¬£¬£¬£¬£¬¸´ºêººÁØÒѽ¨³ÉÒ»Ì廯ÉúÎïÖÆҩƽ̨ £¬£¬£¬£¬£¬£¬¸ßЧ¼°Á¢ÒìµÄ×ÔÖ÷½¹µãÄÜÁ¦¹á´®Ñз¢¡¢Éú²ú¼°ÉÌÒµÔËӪȫ¹¤ÒµÁ´¡£¡£¡£¡£¡£¡£¡£¡£¹«Ë¾Òѽ¨ÉèÍêÉƸßЧµÄÈ«ÇòÑз¢ÖÐÐÄ £¬£¬£¬£¬£¬£¬Æ¾Ö¤¹ú¼ÊGMP±ê×¼¾ÙÐÐÉú²úºÍÖÊÁ¿¹Ü¿Ø £¬£¬£¬£¬£¬£¬Î»ÓÚÉϺ£Ðì»ãµÄÉú²ú»ùµØÒÑ»ñµÃÖйúºÍÅ·ÃËGMPÈÏÖ¤¡£¡£¡£¡£¡£¡£¡£¡£
¸´ºêººÁØÇ°Õ°ÐԽṹÁËÒ»¸ö¶àÔª»¯¡¢¸ßÖÊÁ¿µÄ²úÆ·¹ÜÏß £¬£¬£¬£¬£¬£¬º¸Ç20¶àÖÖÁ¢Òìµ¥¿Ë¡¿¹Ìå £¬£¬£¬£¬£¬£¬²¢ÖÜÈ«Íƽø»ùÓÚ×ÔÓп¹PD-1µ¥¿¹HLX10µÄÖ×ÁöÃâÒßÍŽáÁÆ·¨¡£¡£¡£¡£¡£¡£¡£¡£¼Ìº£ÄÚÊ׸öÉúÎïÀàËÆÒ©ººÀû¿µ?£¨ÀûÍ×Îôµ¥¿¹£©¡¢ÖйúÊ׸ö×ÔÖ÷Ñз¢µÄÖÐÅ·Ë«Åúµ¥¿¹Ò©ÎﺺÇúÓÅ?£¨ÇúÍ×Öéµ¥¿¹ £¬£¬£¬£¬£¬£¬Å·ÃËÉÌÆ·Ãû£ºZercepac?£©¡¢¹«Ë¾Ê׸ö×ÔÉíÃâÒß¼²²¡ÖÎÁƲúÆ·ºº´ïÔ¶?£¨°¢´ïľµ¥¿¹£©Ïà¼Ì»ñÅúÉÏÊÐ £¬£¬£¬£¬£¬£¬¹«Ë¾HLX04±´·¥Öéµ¥¿¹¼°HLX01ÀûÍ×Îôµ¥¿¹Àà·çʪÊàŦÑ×ÐÂ˳Ӧ֢µÄÉÏÊÐ×¢²áÉêÇëÒ²ÕýÔÚÉóÆÀÖС£¡£¡£¡£¡£¡£¡£¡£¹«Ë¾Òàͬ²½¾Í10¸ö²úÆ·¡¢8¸öÍŽáÖÎÁƼƻ®ÔÚÈ«Çò¹æÄ£ÄÚ¿ªÕ¹20¶àÏîÁÙ´²ÊÔÑé £¬£¬£¬£¬£¬£¬¶ÔÍâÊÚȨÖÜÈ«ÁýÕÖÎ÷Å·Ö÷Á÷ÉúÎïÒ©Êг¡ºÍÖÚ¶àÐÂÐ˹ú¼ÒÊг¡¡£¡£¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×
[1]Hu SXC, Yang P, Huang X. An epidemiological survey of uveitis in Southern China. 2002; 2: 1-3.
[2]Zheng Y, Zhang LX, Meng QL, Zhang M, Cui Y, Liu QY, et al. Clinical patterns and characteristics of uveitis in a secondary hospital in southern China. Int J Ophthalmol. 2015;8:337¨C41.?
[3]Yang P, Zhang Z, Zhou H, Li B, Huang X, Gao Y, et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr Eye Res. 2005;30:943¨C8.?
[4]Gao F, Zhao C, Cheng G, Pei M, Liu X, Wang M, et al. Clinical patterns of uveitis in a tertiary center in north China. Ocul Immunol Inflamm. 2017;25(sup1):S1¨CS7
[5]Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine. 2006;33:231-237.
[6]Jaffe G.J. et al, Adalimumab in Patients with Active Noninfectious Uveitis, N Engl J Med 2016;375:932-43.
